Rationale and clinical evidence for the use of gp IIb/IIIa inhibitors in acute coronary syndromes

American Heart Journal

Volumn 135, Issue 4, 1998, Pages

  Braunwald, E ^a   Maseri, A ^a   Armstrong, P W ^a   Califf, R M ^a   Gibler, W B ^a   Hamm, C W ^a   Simoons, M L ^a   Van de Werf, F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HEPTAPEPTIDE; LAMIFIBAN; LEFRADIFIBAN; LOTRIFIBAN; ORBOFIBAN; PLACEBO; SIBRAFIBAN; STREPTOKINASE; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0031981572     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(98)70298-4     Document Type: Article

References (44)

1. J Lefkovits RJ Ivanhoe RM Califf Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction Am J Cardiol 77 1996 1045 1051
2. T Yasuda HK Gold RC Leinbach Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GP IIb/IIIa antibody J Am Coll Cardiol 16 1990 1728 1735
3. P. Constantinides Plaque fissures in human coronary thrombosis J Athero Res 6 1996 1 17
4. MJ Davies AC. Thomas Plaque fissuring—the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina Br Heart J 53 1985 363 373
5. JT. Willerson Conversion from chronic to acute coronary heart disease syndromes: role of platelets and platelet products Tex Heart Inst J 22 1995 13 19
6. E Falk PK Shah V. Fuster Coronary plaque disruption Circulation 92 1995 657 671
7. E. Falk Coronary thrombosis: pathogenesis and clinical manifestations Am J Cardiol 68 1991 28B 35B
8. MA DeWood J Spores R Notske Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction N Engl J Med 303 1980 897 902
9. P. Libby Molecular bases of the acute coronary syndromes Circulation 91 1995 2844 2850
10. A. Maseri Ischemic heart disease: a rational basis for clinical practise and clinical research 1995 Churchill Livingstone New York 237 291
11. D Hackett G Davies A. Maseri Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe Eur Heart J 9 1988 1317 1323
12. WC Little M Constantinescu RJ Applegate Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 78 1988 1157 1166
13. D Hackett J Verwilghen G Davies A. Maseri Coronary stenoses before and after acute myocardial infarction Am J Cardiol 63 1989 1517 1518
14. JA Ambrose MA Tannenbaum D Alexopoulos Angiographic progression of coronary artery disease and the development of myocardial infarction J Am Coll Cardiol 12 1988 56 62
15. D Giroud JM Li P Urban B Meier W. Rutishauser Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography Am J Cardiol 69 1992 729 732
16. AC Van der Wal AE Becker CM van der Loos PK. Das Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology Circulation 89 1994 36 44
17. A Farb AP Burke AL. Tang Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death Circulation 93 1996 1354 1363
18. AC Van der Wal AE Becker KT Koch Clinically stable angina pectoris is not necessarily associated with histologically stable atherosclerotic plaques Heart 76 1996 312 316
19. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 330 1994 956 961
20. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
21. The CAPTURE Investigators Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study Lancet 349 1997 1429 1435
22. P Théroux S Kouz L Roy Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian Lamifiban Study Circulation 94 1996 899 905
23. RA Harrington DJ Moliterno F Van de Werf Delaying and preventing ischemic events in patients with acute coronary syndromes using the platelet glycoprotein IIb/IIIa inhibitor lamifiban [abstract] J Am Coll Cardiol 29 1997 409A
24. White HD. PRISM. Presented at the 46th Annual Scientific Session of the American College of Cardiology; March 16-19, 1997, Anaheim, Calif.
25. Théroux P. PRISM-PLUS. Presented at the 46th Annual Scientific Session of the American College of Cardiology; March 16-19, 1997, Anaheim, Calif.
26. Califf RM. PURSUIT. Presented at the 19th Congress of the European Society of Cardiology; August 24-28, 1997, Stockholm, Sweden.
27. AM Lincoff RM Califf K Anderson Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization J Am Coll Cardiol 30 1997 149 156
28. EJ Topol JJ Ferguson HF Weisman Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention JAMA 278 1997 479 484
29. P Klootwijk S Meij R Melkert ML. Simoons Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE) [abstract] J Am Coll Cardiol 29 1997 367A
30. F. Van de Werf Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes Thromb Haemost 78 1997 210 213
31. RA Harrington DJ Moliterno K Newby Amplification of clinical benefit at six months with the glycoprotein IIb/IIIa inhibitor lamifiban in patients with non ST segment elevation in acute coronary syndromes [abstract] Circulation 96 suppl I 1997 I473
32. Topol EJ. RAPPORT. Presented at the 19th Congress of the European Society of Cardiology; August 24-28, 1997, Stockholm, Sweden.
33. SJ Brener LA Barr J Burchenal A randomized, placebo-controlled trial of abciximab with primary angioplasty for acute MI: the RAPPORT trial [abstract] Circulation 96 suppl I 1997 I473
34. HK Gold BS Coller T Yasuda Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation Circulation 77 1988 670 677
35. T Yasuda HK Gold JT Fallon Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs J Clin Invest 81 1988 1284 1291
36. HK Gold HD Garabedian RE Dinsmore Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans Circulation 95 1997 1755 1759
37. NS Kleiman EM Ohman RM Califf Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study J Am Coll Cardiol 22 1993 381 389
38. Harrington RA. PARADIGM. Presented at the 69th Scientific Sessions of the American Heart Association, November 10-13, 1996, New Orleans, La.
39. EM Ohman NS Kleiman G Gacioch Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: results of a randomized, placebo-controlled dose-ranging trial Circulation 95 1997 846 854
40. Simoons ML. Streptokinase with platelet glycoprotein llb/llla blockade (eptifibatide): an angiographic study. Presented at the 70th Scientific Sessions of the American Heart Association, November 9-12, 1997, Orlando, Fla.
41. J Deckers RM Califf EJ Topol AM Lincoff JE Tcheng ML. Simoons Use of abciximab (ReoPro) is not associated with an increase in the risk of stroke: overview of three randomized trials [abstract] J Am Coll Cardiol 29 suppl A 1997 241A
42. JM Miller EM Ohman JS Schildcrout Survival benefit of abciximab administration during early rescue angioplasty: analysis of 387 patients from the GUSTO-III trial [abstract] J Am Coll Cardiol 31 suppl A 1998 191A
43. CP Cannon CH McCabe S Borzak Randomized trial of an oral platelet glycoprotein llb/llla antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial Circulation 97 1998 340 349
44. M Cohen C Demers EP Gurfinkel A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease N Engl J Med 337 1997 447 452